UNRESECTABLE COLORECTAL CARCINOMA
Clinical trials for UNRESECTABLE COLORECTAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE COLORECTAL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE COLORECTAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo attack on Hard-to-Treat cancers shows early promise
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (which blocks a DNA repair enzyme)—in people with advanced solid tumors that have a HER2 mutation. The goal is to find the safest dose and see if the combo wo…
Matched conditions: UNRESECTABLE COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:28 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in adults with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 participants with…
Matched conditions: UNRESECTABLE COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis study tests whether adding two targeted drugs (LY3214996 and abemaciclib) to the standard drug cetuximab can shrink tumors in people with advanced colorectal cancer that no longer responds to standard treatment. About 46 adults with metastatic or inoperable colorectal cancer…
Matched conditions: UNRESECTABLE COLORECTAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Personalized cell therapy trial for advanced cancers withdrawn before enrollment
Disease control TerminatedThis early-stage trial aimed to test the safety and effectiveness of STIL101, a personalized cell therapy made from a patient's own tumor-fighting T cells, for several advanced cancers including pancreatic, colorectal, kidney, cervical, and melanoma. The treatment involved collec…
Matched conditions: UNRESECTABLE COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC